

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number  
**WO 2005/009437 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/425**,  
C07D 277/34

(21) International Application Number:  
PCT/US2004/023661

(22) International Filing Date: 21 July 2004 (21.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/489,244 21 July 2003 (21.07.2003) US

(71) Applicant (for all designated States except US):  
BETHESDA PHARMACEUTICALS, INC. [US/US];  
404 Windsor Park Dr., Bakersfield, CA 93311 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): AVERY, Mitchell,  
A. [US/US]; 303 Woodland Hills Drive, Oxford, MS  
38655 (US). PERSHADSINGH, Harrihar, A. [US/US];  
404 Windsor Park Dr., Bakersfield, CA 93311 (US).

(74) Agents: BASU, Shantanu et al.; Morrison & Foerster LLP,  
755 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR

(57) Abstract: This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is Sadamantan-2-yl-pentanoic acid [2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl]-methyl-amide is provided.

WO 2005/009437 A1

DOCKETED T8 Jy